Miracell Demonstrates Cognition Impairment and Brain Function Improvement in Severe Alzheimer's Patients Using 'SMART M-CELL'-Based CD34+ Cell-Rich Autologous Blood Concentrate Therapy

---
Miracell Demonstrates Cognition Impairment and Brain Function Improvement in Severe Alzheimer's Patients Using 'SMART M-CELL'-Based CD34+ Cell-Rich Autologous Blood Concentrate Therapy
Vote:
0 0
Previous CGBIO Receives FDA 510(k) Clearance for Patient-Specific Titanium Implant 'EASYMADE TI'
Next iQIYI Returns to LVL UP EXPO 2026 in Las Vegas with Blacklyte, Debuting Peter Pau AI Theater and Immersive AI Experiences

Related News

Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy

Miracell Receives FDA 510(k) Clearance for SMART M-CELL PRP Concentration System and SMART M-CELL Bone Marrow Concentration System

FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial

UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's disease, in its Phase 1 study

Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington's Disease Treatment

Neurophet receives FDA 510(k) Clearance for Neurophet AQUA

menu
menu